<DOC>
	<DOC>NCT00446056</DOC>
	<brief_summary>The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to &lt; 15. The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.</brief_summary>
	<brief_title>Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<criteria>Intermittent asthma, mild persistent asthma, moderate persistent asthma, or severe persistent asthma patients with 2 or more mild or moderate attacks at baseline Patient using antiasthma treatment or therapy including corticosteroids or oral antiallergic drugs Patient with complications that will impair the judgment of efficacy of this drug Patient with convulsive disorders such as epilepsy or such a history Patient with liver disease, renal impairment, heart disease or such other complication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>